NLS Total Current Liabilities from 2010 to 2024
| NLSPW Stock | USD 0.01 0 22.22% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 7.9 M | Current Value 4.5 M | Quarterly Volatility 2.3 M |
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 137.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
NLS | Total Current Liabilities |
Latest NLS Pharmaceutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of NLS Pharmaceutics AG over the last few years. Total Current Liabilities is an item on NLS Pharmaceutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NLS Pharmaceutics AG are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. NLS Pharmaceutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
NLS Total Current Liabilities Regression Statistics
| Arithmetic Mean | 2,647,166 | |
| Geometric Mean | 1,924,733 | |
| Coefficient Of Variation | 88.21 | |
| Mean Deviation | 1,831,168 | |
| Median | 989,955 | |
| Standard Deviation | 2,335,062 | |
| Sample Variance | 5.5T | |
| Range | 6.9M | |
| R-Value | 0.75 | |
| Mean Square Error | 2.6T | |
| R-Squared | 0.56 | |
| Significance | 0 | |
| Slope | 390,953 | |
| Total Sum of Squares | 76.3T |
NLS Total Current Liabilities History
About NLS Pharmaceutics Financial Statements
NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 7.9 M | 4.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.